“In our human genotyping facility sample throughput is critical to our success,” said Andre Uitterlinden of the department of Internal Medicine at Erasmus Medical Center. “When Illumina launched their HumanHap550 BeadChip last year, we used this product in close collaboration with the Department of Epidemiology to study 10,000 individuals for the development of several late-age diseases in the Rotterdam Study. Soon after, Illumina introduced their HumanHap550-Duo BeadChip, which we immediately converted to so that we could double our sample throughput. Now, with the Human610-Quad BeadChip we can increase our throughput four-fold, plus gain access to content only found on Illumina arrays.”
The Generation R Study is conducted in Rotterdam, the second largest city in the Netherlands. The study focuses on four primary areas of research: (1) growth and physical development; (2) behavioral and cognitive development; (3) diseases in childhood; and (4) health and healthcare for pregnant women and children.
“By purchasing another scanner and moving to Illumina’s four-sample BeadChip we are gaining speed and efficiency that is otherwise not available to us. Similar to previous cohort studies initiated by Erasmus Medical Center, we hope that the Generation R Study unveils results that help us contribute to the development of strategies for optimizing health and healthcare for pregnant women and children,” said Professor Albert Hofman, chair of the Generation R Study Group.
The four-sample Infinium HD Human610-Quad BeadChip provides increased sample throughput and reduced handling in the lab. The Human610-Quad BeadChip has 550,000 single nucleotide polymorphisms (SNPs) from the HumanHap550 BeadChip, plus an additional 60,000 genetic markers, including high-value, proprietary CNV content developed in conjunction with deCODE genetics.
“Adoption of our new high-density, four-sample BeadChip for whole-genome association studies demonstrates the confidence that customers, like Erasmus Medical Center, have in Illumina’s BeadArray™ technology,” said Tristan Orpin, Senior Vice President of Illumina’s Commercial Operations. “Combined with the new Human1M-Duo these tools provide our customers with significant advances that will speed the discovery of complex disease.”
About Infinium High-Density (HD) Genotyping
Illumina’s genotyping solutions offer a flexible BeadChip design and high-density architecture. The revolutionary Infinium HD Assay combined with the Infinium HD BeadChip allows large-scale interrogation of variations in the human genome, accelerating the ability of researchers to cost-effectively unlock the genetic basis of disease. Infinium HD products provide a powerful complement to Illumina’s genotyping offering, which includes Infinium II, iSelect™ Infinium, GoldenGate®, and VeraCode™ genotyping products. For more information on Illumina’s HD genotyping products, please visit www.illumina.com.
About Illumina
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of innovative, next-generation life-science tools and integrated systems for the large-scale analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients. “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements Illumina’s ability (i) to integrate effectively our recent acquisition of Solexa, Inc., (ii) to develop and commercialize further our BeadArray(TM), VeraCode(TM) and Solexa(R) technologies and to deploy new gene expression and genotyping products and applications for our technology platforms, (iii) to manufacture robust micro arrays and Oligator(R) oligonucleotides, (iv) to integrate and scale our VeraCode technology, (v) to scale further oligo synthesis output and technology to satisfy market demand derived from our collaboration with Invitrogen, together with other factors detailed in our filings with the Securities and Exchange Commission including our recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. We disclaim any intent or obligation to update these forward-looking statements beyond the date of this release.
Contacts
Illumina Media Contact: Maurissa Bornstein, Public Relations Manager 858-332-4055 mbornstein@illumina.com or
Investor Contact: Peter J. Fromen, Sr. Director, Investor Relations 858-202-4507 pfromen@illumina.com
